EMED Electromedical Technologies, Inc
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1715819 · Fiscal year ends 12/31
Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-35.1%
TTM net income YoY46.3%
TTM EPS YoY—
Revenue 3-yr CAGR2.7%
Net income 3-yr CAGR—
Margins
Gross margin75.1%
Operating margin-109.6%
Net margin-182.0%
FCF margin—
EBITDA margin-109.6%
Returns
ROE—
ROA-236.0%
ROIC (approx.)—
Asset turnover1.30x
Leverage & solvency
Liabilities / assets804.1%
Debt / equity—
Current ratio0.07x
Interest coverage-4.38x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-217.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.35M | $1.15M |
| Cost of revenue | $303,303 | $261,203 |
| Gross profit | $1.05M | $888,641 |
| R&D expense | $231,434 | $92,299 |
| SG&A expense | $3.11M | $2.49M |
| Operating income | -$2.06M | -$1.60M |
| Interest expense | $893,155 | $791,072 |
| Net income | -$2.64M | -$3.47M |
| EBITDA | -$2.06M | -$1.58M |
| EPS (basic) | 0.00 | -0.03 |
| EPS (diluted) | 0.00 | -0.03 |
| Weighted avg. shares (diluted) | 377.22M | 133.60M |
| Balance sheet | ||
| Cash & equivalents | $87,704 | $368,425 |
| Receivables | $4,399 | $9,444 |
| Inventory | $68,517 | $62,061 |
| Current assets | $449,185 | $647,802 |
| PP&E, net | $149,705 | $705,469 |
| Total assets | $748,383 | $1.35M |
| Current liabilities | $3.36M | $2.92M |
| Long-term debt | $150,000 | $671,525 |
| Total debt | $150,000 | $671,525 |
| Total liabilities | $3.62M | $3.57M |
| Shareholders' equity | -$2.87M | -$2.22M |
| Net debt | $62,296 | $303,100 |
| Shares outstanding | 463.29M | 189.78M |
| Cash flow statement | ||
| Operating cash flow | -$1.42M | -$773,337 |
| Capital expenditure | $149,705 | — |
| Free cash flow | -$1.57M | — |
| Investing cash flow | $1.74M | — |
| Financing cash flow | -$608,211 | $758,592 |
| Depreciation & amortization | $4,557 | $21,875 |
| Stock-based compensation | $715,000 | $509,603 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.